Who has been buying Hwail Pharmaceutical stock?

2 distinct insiders have filed 18 disclosed insider purchases in Hwail Pharmaceutical (061250), most recently on 2026-04-09. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.

How many insider filings does Hwail Pharmaceutical have?

Hwail Pharmaceutical has 18 buy-side and 0 sell-side disclosures on record, covering ₩3.0B ($2.1M) in total reported value, spanning 2024-04-17 to 2026-04-09.

Where does StockDrifts get Hwail Pharmaceutical insider data?

From DART D001/D002 insider disclosures — the official filing system run by the Financial Supervisory Service (Korea). StockDrifts parses each disclosure and matches it to daily price history; the original filings remain available directly from DART.

Do insider buys in Korean stocks predict returns?

Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean DART filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

Hwail Pharmaceutical 061250

Company

화일약품Hwail Pharmaceutical

Insiders

Buys

Total Value

₩3.0B ($2.1M)

Avg Return

-11.31%

Last Filing

2026-04-09

Hwail Pharmaceutical (061250) has 18 disclosed insider purchases and 0 disclosed disposals on record, filed by 2 distinct insiders. Together those filings cover ₩3.0B ($2.1M) in reported transaction value. The earliest filing StockDrifts holds for Hwail Pharmaceutical is dated 2024-04-17; the most recent is 2026-04-09. All of it is parsed from DART D001/D002 insider disclosures, the official disclosure system operated by the Financial Supervisory Service (Korea). Across these filings the average return since disclosure is -11.31%, measured from each filing date to the latest available close.

Price & insider activity (12 months)

Recent insider trades

Date	Type	Source	Insider	Position	Shares	Price at filing	Return	Value
2026-04-09	SELL	주식병합	김종호 Kim Jong-ho	Managing Director	-14.6K	₩943	+0.0%	₩14M ($10K)
2026-04-09	SELL	주식병합	신동구 Shin Dong-gu	Managing Director	-19.9K	₩943	+0.0%	₩19M ($13K)
2026-04-09	SELL	주식병합	장순호 Sunho Jang	moving	-32.6K	₩943	+0.0%	₩31M ($21K)
2026-04-09	SELL	주식병합	정정철 Jeong Jeong-cheol	vice president	-14.6K	₩943	+0.0%	₩14M ($10K)
2026-04-09	SELL	주식병합	강성용 Seongyong Kang	moving	-8.2K	₩943	+0.0%	₩8M ($5K)
2026-04-09	SELL	주식병합	오성첨단소재 Ohsung Advanced Materials	-	-19.8M	₩943	+0.0%	₩18.7B ($13.0M)
2026-04-09	SELL	주식병합	박정근 Park Jeong-geun	torture	-5.4K	₩943	+0.0%	₩5M ($4K)
2026-04-09	SELL	주식병합	금호에이치티 Kumho HT	-	-8.3M	₩943	+0.0%	₩7.8B ($5.4M)
2026-03-19	BUY	Market Buy	신동구 Shin Dong-gu	Managing Director	5.0K	-	-	-
2025-08-15	SELL	임원퇴임	박노준 Nojun Park	Managing Director	-16.2K	₩1,163	+7.5%	₩19M ($13K)
2025-08-05	BUY	Market Buy	오성첨단소재 Ohsung Advanced Materials	-	113.5K	₩1,195	-10.0%	₩136M ($94K)
2025-08-04	BUY	Market Buy	오성첨단소재 Ohsung Advanced Materials	-	95.9K	₩1,178	-8.7%	₩113M ($78K)
2025-08-01	BUY	Market Buy	오성첨단소재 Ohsung Advanced Materials	-	37.4K	₩1,165	-7.6%	₩44M ($30K)
2025-07-31	BUY	Market Buy	오성첨단소재 Ohsung Advanced Materials	-	100.1K	₩1,207	-10.8%	₩121M ($84K)
2025-07-30	BUY	Market Buy	오성첨단소재 Ohsung Advanced Materials	-	128.6K	₩1,205	-10.7%	₩155M ($108K)
2025-07-29	BUY	Market Buy	오성첨단소재 Ohsung Advanced Materials	-	153.3K	₩1,209	-11.0%	₩185M ($129K)
2025-07-28	BUY	Market Buy	오성첨단소재 Ohsung Advanced Materials	-	111.5K	₩1,212	-11.2%	₩135M ($94K)
2025-07-25	BUY	Market Buy	오성첨단소재 Ohsung Advanced Materials	-	138.1K	₩1,219	-11.7%	₩168M ($117K)
2025-07-24	BUY	Market Buy	오성첨단소재 Ohsung Advanced Materials	-	150.5K	₩1,206	-10.8%	₩181M ($126K)
2025-07-23	BUY	Market Buy	오성첨단소재 Ohsung Advanced Materials	-	114.8K	₩1,218	-11.7%	₩140M ($97K)
2025-07-22	BUY	Market Buy	오성첨단소재 Ohsung Advanced Materials	-	147.2K	₩1,224	-12.1%	₩180M ($125K)
2025-07-21	BUY	Market Buy	오성첨단소재 Ohsung Advanced Materials	-	200.0K	₩1,225	-12.2%	₩245M ($170K)
2025-07-18	BUY	Market Buy	오성첨단소재 Ohsung Advanced Materials	-	140.5K	₩1,228	-12.4%	₩173M ($120K)
2025-07-17	BUY	Market Buy	오성첨단소재 Ohsung Advanced Materials	-	180.3K	₩1,258	-14.5%	₩227M ($157K)
2025-07-16	BUY	Market Buy	오성첨단소재 Ohsung Advanced Materials	-	226.1K	₩1,230	-12.5%	₩278M ($193K)
2025-07-15	BUY	Market Buy	오성첨단소재 Ohsung Advanced Materials	-	185.3K	₩1,240	-13.2%	₩230M ($160K)
2025-07-14	BUY	Market Buy	오성첨단소재 Ohsung Advanced Materials	-	236.0K	₩1,212	-11.2%	₩286M ($199K)
2025-07-01	SELL	장외매도	금호에이치티 Kumho HT	-	-8.5M	₩1,228	+12.4%	₩10.4B ($7.2M)
2025-07-01	BUY	신규보고	오성첨단소재 Ohsung Advanced Materials	-	19.6M	₩1,228	-12.4%	₩24.1B ($16.7M)
2025-06-09	SELL	임원퇴임	이상래 Lee Sang-rae	Managing Director	-16.2K	₩1,143	+5.9%	₩19M ($13K)
2024-07-30	SELL	시간외매매	CG인바이츠 CG Invites	-	-3.8M	₩1,921	+44.0%	₩7.3B ($5.1M)
2024-05-17	SELL	시간외매매	CG인바이츠 CG Invites	-	-3.8M	₩1,647	+34.7%	₩6.3B ($4.3M)
2024-05-02	SELL	기타	CG인바이츠 CG Invites	-	-2.5M	₩1,635	+34.2%	₩4.1B ($2.8M)
2024-04-18	BUY	CB인수	CG인바이츠 CG Invites	-	2.5M	₩1,590	-32.3%	₩4.0B ($2.7M)
2024-04-17	BUY	제3자배정유상증자	금호에이치티 Kumho HT	-	6.9M	₩1,580	-31.9%	₩10.9B ($7.6M)

Frequently asked questions

Who has been buying Hwail Pharmaceutical stock?: 2 distinct insiders have filed 18 disclosed insider purchases in Hwail Pharmaceutical (061250), most recently on 2026-04-09. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.
How many insider filings does Hwail Pharmaceutical have?: Hwail Pharmaceutical has 18 buy-side and 0 sell-side disclosures on record, covering ₩3.0B ($2.1M) in total reported value, spanning 2024-04-17 to 2026-04-09.
Where does StockDrifts get Hwail Pharmaceutical insider data?: From DART D001/D002 insider disclosures — the official filing system run by the Financial Supervisory Service (Korea). StockDrifts parses each disclosure and matches it to daily price history; the original filings remain available directly from DART.
Do insider buys in Korean stocks predict returns?: Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean DART filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

Source filings

Every trade listed above is disclosed in DART D001/D002 insider disclosures, filed with the Financial Supervisory Service (Korea). View the original DART filings for Hwail Pharmaceutical. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.